• The expression of GFAP is used to distinguish astrocytic neoplasms from epithelial or mesenchymal tumors that may on occasion mimic a glioma [3]. (upmc.edu)
  • This divergent effect might be dependent on the glioma subclass, expression levels of PD-L1 and PD-L1 regulatory molecules, but most importantly on the cell type that express PD-L1 in the tumor microenvironment. (jscimedcentral.com)
  • Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. (jscimedcentral.com)
  • Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. (jscimedcentral.com)
  • In this study, we first used online related databases and related LGG data from TCGA and CGGA to conduct bioinformatics analysis, which confirmed that RUNXs were significantly and positively correlated with immune infiltration in multiple tumors, especially in low-grade glioma (LGG) and there was the highest correlation between RUNXs and the progress and prognosis of LGG. (bjbms.org)
  • The present review focuses on EZH2 signaling in brain tumors including glioma, glioblastoma, astrocytoma, ependymomas, medulloblastoma and brain rhabdoid tumors. (sabanciuniv.edu)
  • The overexpression of LMO3 was correlated with a poor prognosis in glioma patients, and LMO3 was indirectly inhibited by the tumor suppressor miR-101, which is a potential prognosis marker of gliomas. (oncotarget.com)
  • Glioma is a malignant brain tumour ("brain cancer"), and the most common type is glioblastoma multiforme with a poor prognosis. (radiationrefuge.com)
  • Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. (jscimedcentral.com)
  • Aim: Glioblastomas (GBMs) and diffuse intrinsic pontine gliomas (DIPGs) are infiltrating gliomas with poor prognosis. (umn.edu)
  • This study aimed to evaluate the expression of CXCR4 in molecular subtypes of adult and pediatric infiltrating gliomas. (umn.edu)
  • Materials and methods: We evaluated the expression of CXCR4 in 21 DIPGs and 44 adult infiltrating gliomas (25 GBM, 8 astrocytomas, and 11 oligodendrogliomas) by immunohistochemistry. (umn.edu)
  • In adult gliomas, there was a correlation between CXCR4 expression and mutations in EGFR, PIK3CA, TERT promoter, and CDKN2A/B loss. (umn.edu)
  • In contrast, CXCR4 expression was not detected in IDH1/IDH2 mutant gliomas. (umn.edu)
  • It is important to consider CXCR4 expression in clinical trials that evaluate the efficacy of CXCR4 inhibitors in the treatment of gliomas. (umn.edu)
  • [ 1 ] Astrocytoma is one of 3 distinct types of gliomas in the brain, although mixed cell types occur as well. (medscape.com)
  • p.I827N) were detected in 42 (24%) gemistocytic astrocytomas and the olig2 labelling index three patients with gliomas. (who.int)
  • Meningiomas are extragenital tumors, more common in older people, and their prognosis is relatively favorable( overall five-year survival is 81%, a five-year survival rate for meningosarcoma is 55%).The appearance of gliomas is somewhat more predisposed to men, to meningiomas - women. (womensecr.com)
  • Genetic lesions and abnormal gene expression play a major role in the development of gliomas. (womensecr.com)
  • Malignant gliomas - glioblastoma multiforme and anaplastic gliomas( anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma) are the most common infiltrative primary brain tumors. (womensecr.com)
  • Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China. (cdc.gov)
  • All other malignant gliomas including WHO sified anaplastic astrocytoma, anaplastic oligodendroglioma, grade II and III gliomas are composed of 10.2% of all prima- ry CNS tumors in the United State [1] and 5.3% in Korea [2]. (bvsalud.org)
  • WHO grade II tumors include diffuse astrocytomas, oligodendrogliomas and pleomorphic xanthoastrocytomas. (medscape.com)
  • Molecular characterisation revealed that 72.9% of astrocytomas and 63.2% of oligodendrogliomas followed alternative lengthening of telomere (ALT) mechanism to maintain their telomere lengths. (edu.au)
  • To categorize the cases according to the new World Health Organization Central Nervous System classification by reconsidering the histologic features of oligodendrogliomas, astrocytomas and oligoastrocytomas. (balkanmedicaljournal.org)
  • Diffuse glial tumors of the central nervous system are classified by the World Health Organization as astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas according to histological findings (1). (balkanmedicaljournal.org)
  • Oligodendrogliomases have been found that the combined loss of 1p and 19q is closely associated with classical oligodendrogliomas morphology and better prognosis (2). (balkanmedicaljournal.org)
  • Conclusion: CXCR4 is expressed in a subset of DIPGs and GBMs, but it is not expressed in astrocytomas or oligodendrogliomas. (umn.edu)
  • Therefore, the entire oligodendroglial differentiation, diffuse astrocytomas, oligoastrocytomas, coding sequence of the LATS1 gene in IDH1 Mutation, and 1P/19q loSS and oligodendrogliomas. (who.int)
  • 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. (cdc.gov)
  • Like astrocytomas, oligodendrogliomas can evolve into more aggressive forms, such as anaplastic oligodendrogliomas (WHO grade III), which are managed accordingly. (msdmanuals.com)
  • WHO grade I tumors include pilocytic astrocytomas and subependymal giant cell astrocytomas. (medscape.com)
  • WHO grade III tumors include anaplastic astrocytomas and anaplastic pleomorphic xanthoastrocytomas. (medscape.com)
  • Most astrocytomas are indolent low-grade (ie, WHO grade I-II) tumors for which surgical resection alone is sufficient to cure. (medscape.com)
  • The prognosis decreases for low-grade tumors in unresectable locations and remains very poor for high-grade astrocytomas in spite of the addition of radiotherapy and chemotherapy. (medscape.com)
  • According to the 2007 World Health Organization(WHO) classification of tumors of the central nervous system, the WHO defines diffusely astrocytic tumors with cytological atypia as grade II (diffuse astrocytoma), those also showing anaplasia and mitotic activity as grade III (AA), and tumors additionally showing microvascular proliferation and/or necrosis as WHO grade IV. (upmc.edu)
  • Anaplasia may be identified in a subset of tumors with a presumed pilocytic astrocytoma (PA) component or piloid features, which may be associated with aggressive behavior, but the biologic basis of this change remains unclear. (elsevierpure.com)
  • With the help of genetic studies, it is possible to obtain information about diagnosis and prognosis of glial tumors. (balkanmedicaljournal.org)
  • Molecular and cytogenetic examinations also produced results that further contributed to the diagnosis and prognosis of these tumors in addition to the classification performed mostly by histomorphological methods. (balkanmedicaljournal.org)
  • PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. (jscimedcentral.com)
  • The current World Health Organization (WHO) classification of primary brain tumors lists GBM as a grade IV astrocytoma . (medscape.com)
  • Among primary brain tumors, malignant astrocytomas are the most common in all age groups. (medscape.com)
  • EZH2 can be considered as an independent prognostic factor in brain tumors that its upregulation provides undesirable prognosis. (sabanciuniv.edu)
  • Astrocytomas Astrocytomas are central nervous system tumors that develop from astrocytes. (msdmanuals.com)
  • [ 4 ] Genomic analyses of tumors over the past decade have uncovered mutational, copy number, gene expression, and epigenetic alterations in GBMs. (medscape.com)
  • It is unclear whether this process is independent or somehow coordinated with primary pathogenic sarcomere gene mutations, thus interfering with the clinical HCM course and its prognosis. (biomedcentral.com)
  • The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. (justia.com)
  • IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. (cdc.gov)
  • Scope includes mutations and abnormal protein expression. (cancer-genetics.org)
  • In addition, it has to be emphasized, that stromal cells, lymphocytes and endothelial cells in the clinical samples are essential as internal positive tissue controls especially for carcinomas with TP53 mutations causing absence and loss of p53 expression in the tumour cells. (nordiqc.org)
  • Next, hypoxia- and immune-related genes were screened by the LASSO + support vector machine recursive feature elimination (SVM-RFE) and weighted gene co-expression network analysis (WGCNA). (biomedcentral.com)
  • Single-gene enrichment analysis and expression validation of key genes were then performed. (biomedcentral.com)
  • It actively contributes to the pathological processes of these diseases by influencing the expression of various genes. (biomedcentral.com)
  • In the present study, we analyzed prognosis model, immunocyte infiltration characterization, and competing endogenous RNA (ceRNA) network of GBM on the basis of pyroptosis-related genes (PRGs). (researchsquare.com)
  • The present invention relates to the Multiple Tumor Suppressor (MTS) genes in mice, their expression products, and their homology to the human MTS genes. (justia.com)
  • The invention is further related to the use of the MTS genes in the therapy, diagnosis and prognosis of human cancer. (justia.com)
  • Correlations between the expression of endosialin and 13 other genes of interest were also examined. (hindawi.com)
  • The molecular genetics study revealed a mutation in Kras Asp12 gene and altered expression of HMSH2 and HMSH6 proteins encoded by the DNA mismatch repair genes in two of the colonic polyps. (hindawi.com)
  • Interaction with transcription factor OCT2 octamer ATGCAAAT nucleotides is critical and decisive for the expression of immunoglobulin genes. (samatashkhis.com)
  • Exome sequencing was carried out in gemistocytic astrocytomas, and homozygous deletion of genes was identified at 19q13, i.e. (who.int)
  • Enhancer of zeste homolog 2 (EZH2) has obtained much attention in recent years in field of cancer therapy due to its aberrant expression and capacity in modulating expression of genes by binding to their promoter and affecting methylation status. (sabanciuniv.edu)
  • Owing to its enzymatic activity, EZH2 can bind to promoter of target genes to induce methylation and affects their expression. (sabanciuniv.edu)
  • Expression values for each gene were mean centered (mean = 0, stdv = 1), and the sum of the expresion values of the 20 genes for each patient sample was computed (20-gene score, see Materials and Methods). (biomedcentral.com)
  • Transcriptomic meta-analyses reveal significant numbers of genes with inverse patterns of expression in Alzheimer's disease and lung cancer, and with similar patterns of expression in Alzheimer's disease and glioblastoma. (nature.com)
  • As such, we conducted a systematic meta-analysis of transcriptomic gene expression data in AD, GBM and LC, comparing the deregulated genes in each disease to each other. (nature.com)
  • Accordingly, we identified a significant number of genes that were deregulated in opposite directions in AD and LC, inverse expression that was associated to the proteasome, protein folding and mitochondrial processes. (nature.com)
  • This MRI shows a pilocytic astrocytoma of the cerebellum. (medscape.com)
  • Pilocytic astrocytomas (ie, WHO grade I) arise throughout the neuraxis, but preferred sites include the optic nerve, optic chiasm/hypothalamus, thalamus and basal ganglia, cerebral hemispheres, cerebellum, and brain stem. (medscape.com)
  • PMAs have been classified with pilocytic astrocytomas but have been found to have different histologic features and to behave more aggressively than pilocytic astrocytomas. (medscape.com)
  • PMAs have a tendency to disseminate and, in some reports, have a worse prognosis compared with pilocytic astrocytomas. (medscape.com)
  • Pilomyxoid astrocytoma (PMA) is a rare, aggressive variant of pilocytic astrocytoma (PA) that predominantly occurs in the hypothalamic chiasmatic region and is associated with shorter progression-free-survival and overall survival than PA. (aao.org)
  • [2] Clinicians should be aware of the neuro-ophthalmic presentations of PMA and the differences between PMA and typical juvenile pilocytic astrocytoma (JPA). (aao.org)
  • Pilocytic, other low-grade, or anaplastic astrocytomas tend to develop in younger patients. (msdmanuals.com)
  • Thus, even in the setting of a low-grade appearing IDH-mutant astrocytoma without significant mitotic activity, homozygous deletion of CDKN2A and/or CDKN2B would result in a grade 4 designation. (cap.org)
  • DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome. (cdc.gov)
  • Brain involvement includes cortical dysplasias (tubers), subependymal nodules, and/or subependymal giant cell astrocytoma (SEGA), and is seen in almost all cases. (orpha.net)
  • High-grade astrocytomas (HGAs) are slightly more common in whites than in blacks, Latinos, and Asians. (medscape.com)
  • Furthermore within these malignancies vimentin manifestation correlates with accelerated tumor development improved metastatic potential and poorer prognosis [6]. (biotech-angels.com)
  • Patients with a high expression of RUNX1 and/or IFNGR2 (HH/H) in the IDH-mutant subtype showed poorer prognosis and significantly increased infiltration of M2 macrophages. (bjbms.org)
  • Epithelioid cells are associated with more aggressive behavior and carry a poorer prognosis for the patient's survival. (medscape.com)
  • Both DIG and DIA (Desmoplastic infantile astrocytoma) present as large mixed masses under contrast, predominantly containing cystic mass with peripheral solid structure. (frontiersin.org)
  • Objectives: To evaluate the role of cancer stem cell biomarkers in diagnosis and prognosis of OSCC patients. (bvsalud.org)
  • The participants were divided into CD34+ and CD34- groups according to CD34 expression level at diagnosis, and the CD34+ group was further divided into CD34 + CD38- and CD34 + CD38+ subgroups based on CD38 expression level. (bvsalud.org)
  • Thus, exploring novel methods of diagnosis and novel molecular markers which could predict the prognosis of patients with OSCC for is urgently needed for adequate management of OSCC [3]. (scitcentral.com)
  • The current WHO classification of human astrocytomas has limitation in predicting prognosis and diagnosis. (upmc.edu)
  • Features associated with worse prognosis included subtotal resection, adult vs. pediatric, presence of a PA precursor preceding a diagnosis of anaplasia, necrosis, presence of ALT and ATRX expression loss. (elsevierpure.com)
  • All astrocytomas (100%) were given same diagnosis. (balkanmedicaljournal.org)
  • The median survival time following the diagnosis of a glioblastoma is 15 months [ 2 ], and a successful treatment for high-grade astrocytoma is currently lacking. (oncotarget.com)
  • In silico analysis identified the over-expression of carbonic anhydrase 12 (CA12) mRNA in the TP53 wildtype astrocytoma sub-group with the most unfavourable prognosis. (edu.au)
  • Patients with gemistocytic astrocytoma with oligodendroglial differentiation, IDH1 samples from a Li-Fraumeni family with and secondary glioblastoma with RRAS mutation, and 1p/19q loss, suggesting a TP53 germline mutation and multiple deletion tended to have shorter survival that FUBP1 immunohistochemistry is nervous system tumours revealed times than those without deletion. (who.int)
  • MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. (cdc.gov)
  • The authors found that patients who presented with recurrent facial pain in a distribution smaller than their initial presentation had a more favorable prognosis. (surgicalneurologyint.com)
  • IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. (cdc.gov)
  • Glioblastomas, the prognosis of which is highly dependent on the histological grade, are the most common malignancies of the central nervous system in humans. (biomedcentral.com)
  • 17%) gemistocytic astrocytomas and in mutation with a sensitivity of 100% and 3 of 24 (13%) secondary glioblastomas. (who.int)
  • Glioblastomas, the most common astrocytoma histology, have a 5-year relative survival of 5% [ 1 ]. (oncotarget.com)
  • Anaplastic astrocytomas, in particular, can later evolve into glioblastomas (called secondary glioblastomas). (msdmanuals.com)
  • Department of Neurosurgery, toma, NOS, and anaplastic astrocytoma, IDH-wildtype should be treated fol owing the protocol for Incheon St. Mary's Hospital, glioblastomas. (bvsalud.org)
  • The transcriptome and clinical data of 155 patients with GBM and 120 normal subjects were obtained from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx). (researchsquare.com)
  • This study not only laid foundations for further exploring pyroptosis and TME in improving prognosis of GBM, but also provided a new idea for more effective guidance on clinical immunotherapy to patients and developing new immunotherapeutic drugs. (researchsquare.com)
  • Aim of the current study was to investigate ATG16L and LC3B tissue protein expression levels in tissues which were taken from OSCC patients then correlate our results with pathological and clinical patients' data. (scitcentral.com)
  • ATG16L and LC3B expression was assessed in 40 patients with OSCC using immunohistochemistry. (scitcentral.com)
  • ATG16L and LC3B overexpression are markers of poor prognosis in OSCC patients. (scitcentral.com)
  • In this thesis, I have molecularly characterised a retrospective cohort of LGG specimen from 102 patients, including 29 patients with matched primary and recurrent tumours, in order to identify prognostic biomarkers, molecular subgroups with unfavourable prognosis and investigate their potential as therapeutic targets through pre-clinical studies. (edu.au)
  • We also investigated the miRNA-1908 expression in 34 patients according to the postoperative risk of recurrence. (biomedcentral.com)
  • Furthermore, the expression levels of miRNA-1908 were significantly increased in the patients with a high risk of recurrence compared to that observed in the low-risk patients, and this higher expression correlated with a poor survival. (biomedcentral.com)
  • Indeed, mounting evidence has shown that the poor prognosis of patients with glioblastoma and therapeutic failure are associated with a number of abnormally activated signaling pathways, among which phosphoinositide 3-kinase (PI3K)/AKT signaling represents one of the most important regulatory pathways for the malignancy [ 16 , 17 ]. (biomedcentral.com)
  • The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. (cdc.gov)
  • Survival curves for good prognosis (orange line) and poor prognosis (grey line) breast cancer patients according to 70-gene and 76-gene prognosis profiles are showed ( a and b , respectively). (biomedcentral.com)
  • What is the prognosis for glioblastoma patients after Stupp protocol treatment and progression during bevacizumab treatment? (surgicalneurologyint.com)
  • In patients with breast cancer, expression of FLI1 is strongly correlated with advanced stage, poor differentiation, and lymph node metastasis. (biomedcentral.com)
  • To determine the role of FLI1 in breast cancer, we first examined its expression in tumor samples collected from patients with breast cancer. (biomedcentral.com)
  • The present study analyzes the putative prognostic role of RBM3 in a large cohort of patients with urothelial carcinoma (UCA) of the bladder by analyzing RBM3 immunohistochemical expression in various benign urothelial tissues, as well as in invasive and metastatic urothelial lesions. (biomedcentral.com)
  • Patients diagnosed with GB have a dismal prognosis, and typically succumb to the disease within 3 months if untreated. (frontiersin.org)
  • We evaluated a cohort of 94 soft tissue sarcoma samples to assess the correlation between gene expression and protein expression by immunohistochemistry for endosialin and PDGFR- β , a reported interacting protein, across available diagnoses. (hindawi.com)
  • Adenomatous polyps were negative for HMSH2 and HMSH6 [ 5 ] protein expression, which were evaluated by immunohistochemistry (Figure 4 ). (hindawi.com)
  • Clinically, GBM is divided into primary glioblastoma (pGBM), which progresses rapidly and has an absence of precursor lesions, and secondary glioblastoma (sGBM), which progresses as diffuse astrocytoma (WHO grade II) or anaplastic astrocytoma (WHO grade III) [ 2 - 4 ]. (oncotarget.com)
  • Thus, the term secondary glioblastoma for an IDH-mutant astrocytoma that presents with or has progressed with aggressive histology (ie, tumor necrosis or microvascular proliferation) is now termed astrocytoma, IDH-mutant, CNS WHO grade 4 . (cap.org)
  • II) is a rare variant of diffuse astrocytoma, characterized by the presence of neoplastic gemistocytes and a consistent tendency to progress to secondary glioblastoma (WHO grade IV) and have a poor prognosis. (who.int)
  • In some cancers, PD-L1 expression by tumor cells correlates with a good prognosis for the patient, whereas in glioblastoma many reports suggest that it is a bad prognostic marker. (jscimedcentral.com)
  • Glioblastoma, previously known as glioblastoma multiforme (GBM), is the most aggressive and most common type of cancer that originates in the brain, and has very poor prognosis for survival. (wikipedia.org)
  • While CCNA1 methylation was not found to be directly associated with ALT upon investigation, CCNA1 methylation showed a strong trend for association with ALT-associated aberrations in ATRX, and progression-free survival in both the in-house astrocytoma cohort and TCGA dataset. (edu.au)
  • Studies have identified pericytes and reactive fibroblasts, two essential cell types required for tumor survival and growth, as the major sites of expression of endosialin. (hindawi.com)
  • Astrocytomas comprise a wide range of neoplasms that differ in their extent of invasiveness, morphological features, tendency for progression, and clinical course. (medscape.com)
  • Moreover, CCNA1 methylation levels were significantly associated with increasing astrocytoma grade, and it may be involved in tumour progression and aggressiveness. (edu.au)
  • Using semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR) and western blots experiments, we compared changes in ETS-1 and ETS-2 expression, their protein levels, and the regulation of some of their target gene expressions at different stages of the ocular tumoral progression in the transgenic mouse model, Tyrp-1-TAg, with those in normal eyes from control mice of the same age. (molvis.org)
  • Lasso (Least absolute shrinkage and selection operator) Cox expression analysis was used in predicting prognostic markers, and its predictive ability was tested using a nomogram. (researchsquare.com)
  • Pyroptosis and TME-related independent prognostic markers were screened in this study, and a prognosis risk score formula was established for the first time according to the prognosis PRGs. (researchsquare.com)
  • The overall prognosis for GBM has changed little in the past 2 decades, despite major improvements in neuroimaging, neurosurgery, radiation treatment techniques, adjuvant chemotherapy, and supportive care. (medscape.com)
  • IHC evaluation of complex protein expression MMR. (hindawi.com)
  • Often p53 positivity is correlated with high grade lesions (e.g., carcinoma of breast, prostate and bladder, malignant lymphoma) and poor prognosis. (nordiqc.org)
  • Pediatric GBM also has a poor prognosis yet represents a clinically and biologically distinct entity. (medscape.com)
  • Anaplastic astrocytoma (ie, WHO grade III) arises in the same locations as diffuse astrocytomas, with a preference for the cerebral hemispheres. (medscape.com)
  • Under the modified WHO classification, GBM differs from anaplastic astrocytomas (AA) by the presence of necrosis under the microscope. (medscape.com)
  • The association of the molecular variant A-20C of the angiotensinogen gene with the prognosis of human hypertension as determined by the G-6A molecular variant is disclosed. (justia.com)
  • MiR-1908 is a potential new molecular marker for predicting the risk of recurrence and prognosis of glioblastoma. (biomedcentral.com)
  • 80%), little has been known about the molecular profile of gemistocytic astrocytomas. (who.int)
  • The most widely accepted grading schema for astrocytomas is the World Health Organization [WHO] that assigns a grade from I to IV based on the degree of anaplasia of tumor cells, proliferation index values and genetic alterations. (medscape.com)
  • Johannessen AL, Torp SH (2006) The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas Pathol Oncol Res Epub 200612:143-7. (upmc.edu)
  • Firstly, we obtained four HCM-related datasets from the Gene Expression Omnibus (GEO) database for differential expression analysis. (biomedcentral.com)
  • A robust correlation between protein and gene expression data for both endosialin and PDGFR- β was observed. (hindawi.com)
  • MicroRNAs (miRNAs) are small, endogenous noncoding RNAs composed of 18-23 nucleotides (nt) that post-transcriptionally regulate gene expression by targeting the 3'-untranslated regions of mRNAs [ 1 - 3 ]. (biomedcentral.com)
  • Search the gene expression profiles from curated DataSets in the Gene Expression Omnibus (GEO) repository. (cancer-genetics.org)
  • Brain and lung control samples were used to detect basal tissue-associated gene expression in order to rule out confounding data. (nature.com)
  • To date, the significance of ATG16L and LC3B expression in OSCC has not been fully clarified. (scitcentral.com)
  • Treatment of astrocytomas depends on the location and grade of the tumor. (medscape.com)
  • Diffuse astrocytomas (ie, WHO grade II) may arise in any area of the CNS but most commonly develop in the cerebrum, particularly the frontal and temporal lobes. (medscape.com)
  • They show an average value of MIB-1 in the three groups of grade II astrocytoma, AA and glioblastoma multiforme (GBM) of approximately 3,12, and 16 respectively. (upmc.edu)
  • High grade astrocytoma is impressed according to the result of high MIB-1/Ki-67 labeling index and strongly positive reaction with GFAP. (upmc.edu)
  • CD34 expression of these stem cells has been exploited for therapeutic purposes in various hematological disorders. (bvsalud.org)
  • In the last few decades, studies have revealed the presence of CD34 expression on other types of cells with non-hematopoietic origins, such as interstitial cells, endothelial cells, fibrocytes, and muscle satellite cells. (bvsalud.org)
  • Endosialin (CD248, TEM-1) is expressed in pericytes, tumor vasculature, tumor fibroblasts, and some tumor cells, including sarcomas, with limited normal tissue expression, and appears to play a key role in tumor-stromal interactions, including angiogenesis. (hindawi.com)
  • Hatten ME, Shelanski ML. Mouse cerebellar granule neurons arrest the proliferation of human and rodent astrocytoma cells in vitro. (jscimedcentral.com)
  • Both 2D monolayer and 3D neurospheres were successfully cultured and characterized for proliferative potential, intrinsic plasticity, presence of cancer stem cells and the expression of stem cell markers. (frontiersin.org)
  • MiR-101 decreased the expression of LMO3 by reversing the methylation status of the LMO3 promoter and by inhibiting the presence of the methylation-related histones H3K4me2 and H3K27me3 and increasing the presence of H3K9me3 and H4K20me3 on the promoter. (oncotarget.com)
  • In dysplastic lesions, e.g., in Barrett's esophagus, p53 expression increases the risk of carcinoma. (nordiqc.org)
  • Within cohorts of soft tissue diagnoses assembled by tissue type (liposarcoma, leiomyosarcoma, undifferentiated sarcoma, and other), endosialin expression was significantly correlated with a better outcome. (hindawi.com)
  • Besides, we also found that the expression levels of RUNX1 and IFNGR2 were significantly reduced, and their correlation was enhanced in the IDH-mutant subtype. (bjbms.org)